Inhibition of mitochondrial cytochrome C oxidase by dicarbanonaborates

Z Drahota1, M Vrbacký, H Rauchová

  • 1Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

Biochemistry and Molecular Biology International
|August 1, 1996
PubMed

Insights

Dicarbanonaborates were found to inhibit mitochondrial cytochrome c oxidase. Unlike other enzymes, this inhibition was non-competitive, suggesting varied mechanisms for dicarbanonaborate effects on mitochondrial enzymes.

Area of Science:

  • Biochemistry
  • Mitochondrial Biology
  • Enzyme Kinetics

Background:

  • Mitochondrial membrane-bound enzymes are crucial for cellular respiration.
  • Understanding drug interactions with these enzymes is vital for pharmacology.
  • Dicarbanonaborates are a class of compounds with potential biological activity.

Purpose of the Study:

  • To investigate the mechanism by which dicarbanonaborates affect mitochondrial membrane-bound enzymes.
  • To specifically characterize the inhibition of mitochondrial cytochrome c oxidase by dicarbanonaborates.

Main Methods:

  • Enzyme activity assays were performed using isolated mitochondria.
  • Kinetic analysis was employed to determine the mode of inhibition for cytochrome c oxidase.
  • Comparisons were made with the inhibition patterns of mitochondrial ATPase and glycerol phosphate dehydrogenase.

Main Results:

  • Dicarbanonaborates were confirmed to inhibit mitochondrial cytochrome c oxidase activity.
  • The inhibition of cytochrome c oxidase was non-competitive.
  • A significant drug-insensitive residual activity of cytochrome c oxidase was observed.

Conclusions:

  • Dicarbanonaborates exhibit distinct inhibitory mechanisms against different mitochondrial membrane-bound enzymes.
  • The non-competitive inhibition of cytochrome c oxidase suggests a unique interaction compared to other mitochondrial enzymes studied.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Electron Transport Chain: Complex III and IV01:43

Electron Transport Chain: Complex III and IV

During the electron transport chain, electrons from NADH and FADH2 are first transferred to complexes I and II, respectively. These two complexes then transfer the electrons to ubiquinol, which carries them further to complex III. Complex III passes the electrons across the intermembrane space to Cyt c, which carries them further to complex IV. Complex IV donates electrons to oxygen and reduces it to water. As electrons pass through complexes I, III, and IV, the energy released aids the pumping...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...